📰 Refractory Lymphomas News
Refractory Lymphomas News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Refractory Lymphomas. Real-time updates on events, politics, business and more.
December 11, 2023
STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma and Hodgkin’s lymphoma Robust STAT3...
June 14, 2023
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor... | June 14, 2023
June 10, 2023
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose
June 9, 2023
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...
June 9, 2023
Data shared today in abstracts from the International Conference on Malignant Lymphoma Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose... | June 10, 2023
December 11, 2022
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting